NeuroSense Completes Safety Analysis of PrimeC in Alzheimer's Phase 2 Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Safety Analysis Completed: NeuroSense has completed the safety analysis of its PrimeC combination in the Phase 2 clinical trial for Alzheimer's disease, revealing a favorable tolerability profile with no serious adverse events reported, indicating potential safety for clinical application.
- Data Analysis Plan: The company plans to analyze clinical observations alongside biomarker data, with results expected in Q1 2026, which will provide a more comprehensive understanding of PrimeC's efficacy and could influence future treatment strategies.
- Alzheimer's Disease Context: Alzheimer's disease affects over 30 million people globally, and existing therapies offer only limited symptomatic relief; PrimeC's multi-mechanism targeting strategy holds promise to address this significant unmet medical need.
- NeuroSense's Mission: As a clinical-stage biotechnology company, NeuroSense focuses on developing treatments for neurodegenerative diseases, and the success of PrimeC could bring new hope to ALS and Alzheimer's patients, enhancing the company's leadership position in this field.
NRSN
$0.85+Infinity%1D
Analyst Views on NRSN
Wall Street analysts forecast NRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRSN is 8.25 USD with a low forecast of 7.50 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.810
Low
7.50
Averages
8.25
High
9.00
Current: 0.810
Low
7.50
Averages
8.25
High
9.00
About NRSN
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
